Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study.

[1]  M. González-Gay,et al.  Cardiovascular risk assessment according to a national calibrated score risk index in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. , 2014, Joint, bone, spine : revue du rhumatisme.

[2]  L. Punzi,et al.  Impact of hypertension on vascular remodeling in patients with psoriatic arthritis , 2014, Journal of Human Hypertension.

[3]  L. Punzi,et al.  Serological markers in psoriatic arthritis: promising tools , 2013, Experimental biology and medicine.

[4]  L. Punzi,et al.  Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients , 2013, Clinical Rheumatology.

[5]  D. Gladman,et al.  The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease , 2013, Annals of the rheumatic diseases.

[6]  S. Rong,et al.  TNF-α induces endothelial dysfunction via PKC-ζ-dependent NADPH oxidase activation , 2012, Journal of Huazhong University of Science and Technology [Medical Sciences].

[7]  L. Punzi,et al.  Psoriatic arthritis. When the heterogeneity requires normality. , 2012, Reumatismo.

[8]  M. Puato,et al.  Osteoprotegerin levels are increased in patients with venous thromboembolic disease , 2012, Journal of Thrombosis and Haemostasis.

[9]  J. Biton,et al.  TNFα: activator or inhibitor of regulatory T cells? , 2012, Joint, bone, spine : revue du rhumatisme.

[10]  L. Punzi,et al.  A comparative study of serum and synovial fluid lipoprotein levels in patients with various arthritides. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[11]  S. Lestre,et al.  Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. , 2011, European journal of dermatology : EJD.

[12]  L. Punzi,et al.  Atherosclerosis in psoriatic arthritis. , 2011, Autoimmunity reviews.

[13]  M. Dougados,et al.  European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies , 2011, Annals of the rheumatic diseases.

[14]  L. Punzi,et al.  [Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data]. , 2011, Reumatismo.

[15]  G. Di Minno,et al.  Carotid Intima-Media Thickness in Psoriatic Arthritis: Differences Between Tumor Necrosis Factor-&agr; Blockers and Traditional Disease-Modifying Antirheumatic Drugs , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[16]  J. Hansen,et al.  Relation between serum osteoprotegerin and carotid intima media thickness in a general population – the Tromsø Study , 2010, Journal of thrombosis and haemostasis : JTH.

[17]  G. Mazzoccoli,et al.  Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients , 2010, Internal and emergency medicine.

[18]  Cheuk-Man Yu,et al.  Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study , 2010, Annals of the rheumatic diseases.

[19]  M. Nurmohamed,et al.  Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study , 2010, Annals of the rheumatic diseases.

[20]  E. Schwarz,et al.  CD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritis , 2010, Arthritis research & therapy.

[21]  F. Salaffi,et al.  The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people , 2009, Health and quality of life outcomes.

[22]  P. Palatini,et al.  Increase in Carotid Intima-Media Thickness in Grade I Hypertensive Subjects: White-Coat Versus Sustained Hypertension , 2008, Hypertension.

[23]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[24]  L. Punzi,et al.  Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. , 2007, Autoimmunity reviews.

[25]  Javier Martín,et al.  Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. , 2007, Arthritis and rheumatism.

[26]  T. Rabelink,et al.  Endothelial function and dysfunction: testing and clinical relevance. , 2007, Circulation.

[27]  Marcello Demi,et al.  A System for Real-Time Measurement of the Brachial Artery Diameter in B-Mode Ultrasound Images , 2007, IEEE Transactions on Medical Imaging.

[28]  M. Bala,et al.  Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. , 2006, The Journal of rheumatology.

[29]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[30]  M. Cutolo,et al.  Effects of Anti‐TNF‐α Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis , 2006 .

[31]  A. Reiss,et al.  Atherosclerosis: Immune and Inflammatory Aspects , 2006, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[32]  M. Cerinic,et al.  Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases , 2005, Circulation.

[33]  J. Girón-González,et al.  Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[34]  Misra Sn,et al.  Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. , 2005 .

[35]  Y. Shoenfeld,et al.  Inflammation and accelerated atherosclerosis: basic mechanisms. , 2005, Rheumatic diseases clinics of North America.

[36]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[37]  E. Vicaut,et al.  Mannheim Intima-Media Thickness Consensus , 2004, Cerebrovascular Diseases.

[38]  C. Ritchlin,et al.  Patterns of cytokine production in psoriatic synovium. , 1998, The Journal of rheumatology.

[39]  P Pignoli,et al.  Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. , 1986, Circulation.

[40]  G. Kersley.  European League Against Rheumatism , 1951 .

[41]  Gian Paolo Rossi,et al.  Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. , 2005, Journal of hypertension.

[42]  Gian Paolo Rossi,et al.  Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. , 2005, Journal of hypertension.